Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 561-569

  Stefani, S ^a   Mezzatesta, M L ^a   Fadda, G ^b   Mattina, R ^c   Palu G ^d   Rossano, F ^e   Tufano, M A ^f   Schito, Gian Carlo ^g   Nicoletti, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Antimicrobials; CARTI; Cefditoren; Gram negative; Gram positive; MIC

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFDITOREN; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; LEVOFLOXACIN; METICILLIN; PENICILLIN DERIVATIVE; PENICILLIN G;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; DRUG INDICATION; DRUG POTENCY; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; ITALY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 57049110576     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.561     Document Type: Article

References (59)

1. Mandell LA. Antimicrobial resistance and treatment of community-acquired pneumonia. Clin. Chest Med. 2005; 26(1):57-64.
2. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens.: Int. J. Antimicrob. Agents. 2007; 30 Suppl 2:S135-8.
3. Bisno AL. Acute pharyngitis. N Engl J Med. 2001; 344(3):205-11.
4. Passàli D, Lauriello M, Passàli GC, Passàli FM, Bellussi L. Group A streptococcus and its antibiotic resistance. Acta Otorhinolaryngol. Ital. 2007; 27(1):27-32.
5. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 2007; 20(2):368-89.
6. Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin. Microbiol. Rev. 2002; 15(1):125-44.
7. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004; 50 Suppl 1:3-10.
8. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol. 2007;10(5):428-35.
9. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis. 2007; 45 Suppl 3:S165-70.
10. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006; 34(5 Suppl 1):S20-8; discussion S64-73.
11. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol. 2007 Oct; 7(5):459-69. Epub 2007 Sept 17.
12. Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs. 2002; 62(2):319-36; discussion 337-8.
13. Wellington K, Curran MP. Spotlight on cefditoren pivoxil in bacterial infections. Treat Respir Med. 2005; 4(2):149-52.
14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: seventeenth informationals supplement. CLSI document M100-S17.CLSI, Wayne, Pennsylvania 2007.
15. Tamura A, Okamoto R, Yoshida T, Yamamoto H, Kondo S, Inoue M et al. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1998 Sep; 32(9):1421-6.
16. Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis. 2001; 41(1-2):1-14.
17. Reinert RR, Al-Lahham A, Lütticken R. In vitro activity of cefditoren against clinical isolates of penicillin-susceptible and penicillin-intermediate strains of Streptococcus pneumoniae isolated in Germany, 1992-1998. J Antimicrob Chemother. 2001; 48(2):279-81.
18. Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR, Appelbaum PC. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother. 2002;50(1):33-41.
19. Lee MY, Ko KS, Ch WS, Park S, Lee JY, Baek JY et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents. 2006; 28(1):14-8.
20. Fenoll A, Giménez MJ, Robledo O, Coronel P, Gimeno M, Casal J et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents. 2007; 29(2):224-6.
21. Perez-Trallero E, Marimon JM, Ercibengoa M, Gimenez MJ, Coronel P, Aguilar L. Antimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 2007; 13: 937-940.
22. Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M et al. Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity. Eur J Clin Microbiol Infect Dis. 2008; 26.
23. Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Echeverría O et al. Beta-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: an in vitro pharmacodynamic simulation. Chemotherapy. 2008; 54(2):84-90.
24. Schito GC. Is antimicrobial resistance also subject to globalisation? Clin Microbiol Infect 2002; 8 Suppl 3:1-8; discussion 33-5.
25. Marchese A, Schito GC. Role of global surveillance in combating bacterial resistance. Drugs. 2001; 61; 167-73.
26. Boccia D, D'Ancona F, Salmaso S, Monaco M, Del Grosso M, D'Ambrosio F et al.. Antibiotic-resistance in Italy: activity of the first year of the surveillance project AR-ISS. Ann Ig. 2005;17(2):95-110.
27. Marchese A, Gualco L, Cochetti I, Montanari MP, Speciale AM, Musumeci SR et al. Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002). Int J Antimicrob Agents. 2005; 138-45.
28. Cascone C, Mezzatesta ML, Santagati M, Cafiso V, Nicoletti G, Stefani S. Activity of telithromycin against multi-drug resistant Streptococcus pneumoniae and molecular characterization of macrolide and tetracycline resistance determinants. J Chemother. 2005;17(5):502-8.
29. Marchese A, Ardito F, Fadda G, Gualco L, Mezzatesta M, Nicoletti G et al. Protekt Italia. Analisi dei risultati del terzo e ultimo anno di studio (2004) e considerazioni conclusive. GIMMOC. 2005; Vol. IX, n.2: 69-106
30. Monaco M, Camilli R, D'Ambrosio F, Del Grosso M, Pantosti A. Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy. J Antimicrob Chemother 2005; 55, 256-259.
31. Mazzariol A, Koncan R, Bahar G, Cornaglia G. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study, J Chemother 2007; 19(5): 500-7.
32. Varaldo PE, Debbia EA, Nicoletti G, Pavesio D, Ripa S, Schito GC et al. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group. Clin Infect Dis 1999; 29(4): 869-73.
33. Cascone C, Santagati M, Noviello S, Iannelli F, Esposito S, Pozzi G et al. Macrolide-resistance genes in clinical isolates of Streptococcus pyogenes Microb Drug Resist. 2002;8(2):129-32.
34. Gagliotti C, Nobilio L, Milandri M, Moro ML. for the Emilia-Romagna Antibiotic Resistance Study Group. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes. Antimicrob Agents Chemother 2006; 42: 1153-56.
35. Creti R, Imperi M, Baldassarri L, Pataracchia M, Recchia S, Alfarone G et al. emm Types, virulence and antibiotic resitance of invasive Streptococcus pyogenes isolates from Italy: what has changed in 11 years? J Clin Microbiol. 2007; 45(7):2249-2256.
36. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003; 9 (12): 1179-86.
37. Blandino G, Marchese A, Ardito F, Fadda G, Fontana R, Lo Cascio G et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolates in Italy from patients with hospital-acquired infections. Int J Anthmicrob Agents 2004; 24(5):515-8.
38. Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis. 2005 Oct; 11(10):1647-8.
39. Nicoletti G, Blandino G, Caccamo F, Fruscia O, Schito AM, Speciale A; Italian Epidemiologial Observatory. The Italian Epidemiological Survey 1997-1999. Antimicrobial susceptibility data of Hoemophylus influenzae, Hoemophylus parainfluenzae and Moraxella catarrhalis in Italy. Int J Antimicrob Agents. 2002; 20(4): 263-9.
40. Schito AM, Schito GC, Debbia E, Russo G, Liñares J, Cercenado E et al. Antibacterial resistance in Streptococcus pneumoniae and Haemophylus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000. J Chemother 2003; 15(3): 226-34.
41. Cerquetti M, Cardines R, Giufrè M, Mastrantonio P; HI Study Group. Antimicrobial susceptibility of Haemophilus influenzae strains isolates from invasive diseases in Italy. J Antimicrob Chemother 2004; 54(6): 1139-43.
42. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother. 2006; 58(4):873-7.
43. Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae: an Italian survey. Int J Antimicrob Agents. 2002; 19(3): 213-7.
44. Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G et al. Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006; 44(5): 1659-64.
45. Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, Arnicosante G et al. CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging country-wide problem. Antimicrob Agents Chemother 2006; 50(8): 2700-6.
46. Carattoli A, Garcia-Fernández A, Varesi P, Fortini D, Gerardi S, Penni A et al. Molecular epidemiology of Escherichia coli producing extended beta-lactamases isolated in Rome, Italy. J C)in Microbiol 2008; 46(1): 103-8.
47. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar L. Antimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect. 2007;13:937-40.
48. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ et al. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2008; 27(1):75-80.
49. Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007; 51(11):3902-7.
50. Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis. 2002; 42(1):59-64.
51. Karlowsky JA, Critchley IA, Draghi DC, Jones ME, Thornsberry C, Sahm DF. Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis. 2002; 42(1):53-8.
52. Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ et al. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Hoemophilus influenzae recovered from children with acute otitis media. J Antimicrob Chemother. 2007; 60(2):323-7.
53. Jones RN, Biedenbach DJ, Johnson DM. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis. 2000; 37(2):143-6.
54. Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs. 2002; 62:319-36;]
55. Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004; 64(22):2597-618.
56. Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006; 50(5):1762-7.
57. Granizo JJ, Giménez MJ, Barberán J, Coronet P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the perpathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006; 28(12):2061-9
58. Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cepherns in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):31S-38S. Review.
59. Esposito S, Ianniello F, Noviello S, Leone S, Ascione T, Tice A et al. Outpatient Parenteral Antibiotic Therapy (OPAT): the Italian registry. Infez Med. 2002; 3:169-75.